NRG-103

AXP000060.1 · Oncolytic virus

Platform
adenovirus
Sponsor
Zhongnan Hospital of Wuhan University

Names

NameTypeSource
NRG-103preferred name, codecurator, ctgov

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus (serotype not reported)
Replication
conditionally replicating
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07710690A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade GliomaRecruitingPhase 12026-07-092030-04-3024HGG; High Grade Glioma; High Grade Glioma (III or IV)
NCT06757153Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma PatientsRecruitingEarly phase 12024-12-192027-0815Glioblastoma (GBM)

Recent changes

No changes recorded in its trials yet.

Notes

Oncolytic adenovirus in an early-phase trial at Zhongnan Hospital (NCT06757153). Construct, transgenes and originator not found; entered on the strength of the trial registration alone.

How to cite

NRG-103 (AXP000060.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000060.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.